WO2001045669A1 - Utilisation therapeutique de particules presentant des fractions de liaison specifiques de pathogenes - Google Patents

Utilisation therapeutique de particules presentant des fractions de liaison specifiques de pathogenes Download PDF

Info

Publication number
WO2001045669A1
WO2001045669A1 PCT/US2000/035076 US0035076W WO0145669A1 WO 2001045669 A1 WO2001045669 A1 WO 2001045669A1 US 0035076 W US0035076 W US 0035076W WO 0145669 A1 WO0145669 A1 WO 0145669A1
Authority
WO
WIPO (PCT)
Prior art keywords
particle
binding moiety
pathogen
sep
binding
Prior art date
Application number
PCT/US2000/035076
Other languages
English (en)
Inventor
Joshua Lederberg
Original Assignee
Elusys Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elusys Therapeutics, Inc. filed Critical Elusys Therapeutics, Inc.
Priority to AU25939/01A priority Critical patent/AU2593901A/en
Priority to US10/168,855 priority patent/US20040033584A1/en
Publication of WO2001045669A1 publication Critical patent/WO2001045669A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10351—Methods of production or purification of viral material

Abstract

L'invention concerne l'utilisation thérapeutique de particules qui sont efficacement supprimées du circuit sanguin, ces particules présentant des fractions de liaison spécifiques de pathogènes servant à chaperonner la suppression de substances potentiellement nuisibles présentes dans le circuit sanguin d'un vertébré. L'invention concerne également des méthodes de traitement, de diagnostic ou de recherche par criblage de maladies et de troubles associés à la présence des pathogènes. L'invention concerne en outre des compositions pharmaceutiques et des trousses de diagnostic contenant la particule thérapeutique qui présente la fraction de liaison aux pathogènes selon l'invention.
PCT/US2000/035076 1999-12-23 2000-12-21 Utilisation therapeutique de particules presentant des fractions de liaison specifiques de pathogenes WO2001045669A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU25939/01A AU2593901A (en) 1999-12-23 2000-12-21 Therapeutic use of particles displaying pathogen-specific binding moieties
US10/168,855 US20040033584A1 (en) 2000-12-21 2000-12-21 Therapeutic use of particles displaying pathogen-specific binding moieties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17194899P 1999-12-23 1999-12-23
US60/171,948 1999-12-23

Publications (1)

Publication Number Publication Date
WO2001045669A1 true WO2001045669A1 (fr) 2001-06-28

Family

ID=22625754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035076 WO2001045669A1 (fr) 1999-12-23 2000-12-21 Utilisation therapeutique de particules presentant des fractions de liaison specifiques de pathogenes

Country Status (2)

Country Link
AU (1) AU2593901A (fr)
WO (1) WO2001045669A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081242B1 (en) 1999-11-28 2006-07-25 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
US7405342B2 (en) 2003-05-09 2008-07-29 University Of Massachusetts Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BELAY ET AL.: "Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model", JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, vol. 29, 1991, pages 419 - 421, XP002939698 *
JONES ET AL.: "Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes", BIOCHIMICA AND BIOPHYSICA ACTA, vol. 1147, 1993, pages 251 - 261, XP002939699 *
MORENKOV ET AL.: "Isolation of mutants of Aujeszky's disease virus with antigenically altered glycoprotein E by affinity chromatography using monoclonal antibodies", JOURNAL OF VIROLOGICAL METHODS, vol. 77, 1999, pages 101 - 108, XP002939700 *
NORLEY ET AL.: "Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: An effective means of inhibiting virus replication in vitro", JOURNAL OF IMMUNOLOGY, vol. 136, no. 2, 15 January 1986 (1986-01-15), pages 681 - 685, XP002939695 *
SINGH ET AL.: "Use of specific polyclonal antibodies for site specific drug targeting to malaria infected erythrocytes in vivo", INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, vol. 30, no. 6, 1993, pages 411 - 413, XP002939697 *
SNYDER JR. ET AL.: "Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A-silica matrix", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 101, 1987, pages 209 - 217, XP002940001 *
TAYLOR ET AL.: "Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model", JOURNAL OF IMMUNOLOGY, vol. 159, 1997, pages 4035 - 4044, XP002939694 *
YIP ET AL.: "Biodistribution of filamentous phage-Fab in nude mice", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 225, 27 May 1999 (1999-05-27), pages 171 - 178, XP002939696 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081242B1 (en) 1999-11-28 2006-07-25 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
US7405342B2 (en) 2003-05-09 2008-07-29 University Of Massachusetts Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire

Also Published As

Publication number Publication date
AU2593901A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
US20210308242A1 (en) Fusion proteins comprising an anti-cd40 antibody and cancer antigens
EP0698091B1 (fr) Procede de preparation d'immunogenes ou de reactifs de diagnostic, et immunogenes ou reactifs de diagnostic pouvant etre obtenus par ce procede
CN105837691B (zh) 靶向抗原呈递细胞的癌症疫苗
US6743893B2 (en) Receptor-mediated uptake of peptides that bind the human transferrin receptor
US5885577A (en) Antigen binding peptides (abtides) from peptide libraries
US20170114142A1 (en) Anti-cd40 antibodies and uses thereof
EP2205736B1 (fr) Méthode de préparation d'un composé immunogénique contre le VIH à base d'anticorps spécifiques pour HIV
US20040033584A1 (en) Therapeutic use of particles displaying pathogen-specific binding moieties
EA010785B1 (ru) Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение
Manoutcharian et al. Phage displayed biomolecules as preventive and therapeutic agents
SA96170384B1 (ar) وطرق تحضيرها واستخداماتها العلاجية (rsv) الاجسام المضادة المعادلة البشرية احادية النسيلة ذات الالفة العالية المختصة ببروتين - ف للفيروس المخلوي التنفسي
AU3719395A (en) Antigen binding peptides (abtides) from peptide libraries
CA2518944A1 (fr) Inhibiteurs de proteines de choc thermique (hsp90) extracellulaires
US20100284967A1 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
Fadaie et al. Unraveling the potential of M13 phages in biomedicine: Advancing drug nanodelivery and gene therapy
WO2001045669A1 (fr) Utilisation therapeutique de particules presentant des fractions de liaison specifiques de pathogenes
US20090155272A1 (en) Targeted pharmaceuticals and ligands
JP4190005B2 (ja) 結合性分子の選択方法
WO1998003544A1 (fr) IDENTIFICATION DE SEQUENCES PEPTIDIQUES COURTES REPRESENTANT DES EPITOPES DE LA GLYCOPROTEINE G DE HSV-2, AU MOYEN D'UNE BANQUE D'AFFICHAGE DE PEPTIDES PHAGES UTILE DANS UN DOSAGE ELISA ANTI-gG2
US6964843B1 (en) Methods and reagents for the detection of antibodies to adenovirus
WO2013185193A1 (fr) Procédé de production et d'obtention de variables de fragment fab de l'anticorps monoclonal anti-digoxine à partir de la technique de clonage en biologie moléculaire
JPH10509237A (ja) 中和抗体の誘発のための防御抗原を同定する方法
van Houten et al. Phage libraries for developing antibody-targeted diagnostics and vaccines
Manoutcharian Phage vaccines and phage therapy
Hida Virus penetration through human mucus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10168855

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP